P. Bang

发表

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.

T. Ottenhoff, T. Ottenhoff, P. Andersen, 2010, Vaccine.

Human Plasma‐Derived Mannose‐Binding Lectin: A Phase I Safety and Pharmacokinetic Study

M. Christiansen, S. Saevarsdottir, J. Gudjonsson, 2004, Scandinavian journal of immunology.

Development, Manufacturing and Characterization of a Highly Purified, Liquid Immunoglobulin G Preparation from Human Plasma

G. Houen, P. Bang, I. Laursen, 2014, Transfusion Medicine and Hemotherapy.

First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses

T. Ottenhoff, P. Andersen, T. M. Doherty, 2010, Human vaccines.

Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.

B. Mordmüller, P. Kremsner, S. Sirima, 2021, Vaccine.

Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth

A. Aseffa, Martha Zewdie, A. Hailu, 2012, BMC Research Notes.

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.

P. Andersen, A. Fomsgaard, G. Gram, 2011, Vaccine.

Safety and Immunogenicity of H1/IC31H, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial

T. Scriba, W. Hanekom, K. Reither, 2015 .

Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial

T. Scriba, W. Hanekom, K. Reither, 2014, PloS one.

A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

A. Aseffa, Martha Zewdie, J. Ahmed, 2018, Trials.

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.

T. Ottenhoff, T. Ottenhoff, P. Andersen, 2011, Vaccine.

H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.

M. Hatherill, T. Scriba, W. Hanekom, 2017, Vaccine.

Low levels of mannose‐binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy

M. Christiansen, N. E. Hansen, C. Koch, 2003, European journal of haematology.

Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth

A. Aseffa, Martha Zewdie, A. Hailu, 2012, BMC Research Notes.

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.

Courtney R. Plumlee, D. Sherman, A. Sette, 2017, Cell host & microbe.

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.

M. Tameris, M. Hatherill, T. Scriba, 2015, Vaccine.

A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.

M. Christiansen, B. Mordmüller, S. Issifou, 2016, Vaccine.

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.

K. Stagliano, P. Andersen, J. Sadoff, 2010, Vaccine.

Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells

U. Certa, K. Reither, P. Andersen, 2015, Clinical and Vaccine Immunology.

A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients

Inge Christoffer Olsen, K. Taskén, R. Mortensen, 2021, Nature Communications.

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

P. Andersen, R. Shattock, K. Korsholm, 2019, The Lancet. Infectious diseases.

Antigen Availability Shapes TCell Differentiation and Function during Tuberculosis Graphical

D. Sherman, A. Sette, H. Maecker, 2022 .

The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia

M. Christiansen, J. Schierbeck, H. Valdimarsson, 2008, Scandinavian journal of infectious diseases.